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i.HLA COMPATIBILITY has been widely 
recognized to improve the outcome of 
lddneyl.2 and probably heart transplants3 but 
no beneficial effect has been reported for liver 
transplants.4-6 Neither pretransplant HLA-
specific antibodies nor a positive donor-
specific I:[ossmatch seems to decrease liver 
allograft survival. 7·9 Recent studies have 
shown HLA-specific alloreactive T cells in 
lymphocyte cultures grown from hepatic allo-
grafts, providing evidence that HLA antigens 
are involved in cellular immune mechanisms 
leading to rejection of liver allografts. 10.1 I We 
have recently reexamined the question of 
whether HLA compatibility influences liver 
transplant survival. This paper briefly sum-
marizes the results of this analysis, a more 
detailed report will appear elsewhere. 12 
METHODS AND RESULTS 
This ,(udv was conducted on more than 500 primary 
grafts and retransplants. The overall actuarial graft sur-
vival was 59% at I year and 55% at 2 years. We observed 
that HLA compatibility was associated with lower sur-
vival rates of liver allografts. For the HLA-A locus, liver 
transplants with zero mismatches (n - 42) did worse than 
those with one or two mismatched antigens (n - 532). 
One-year graft survivals were 41.1% and 61.6%, and 
2-year graft survivals were 37.5% and 56.7%, respec-
tively. The differences between the zero v one and two 
HLA-A mismatch groups were statistically significant. 
Although a similar trend was noted for HLA-8 compati-
bility, insufficient numbers of zero HLA-8 antigen mis-
matches were available for a meaningful statistical analy-
sis. 
Similarly, liver transplants with zero HLA-DR mis-
m.'h:nes shared lower survival rates than the group with 
on~ :lnd two HLA-DR mismatches. The I-year and 
2-year graft survivals were 51.9% v 60.3%, and 45.0% v 
56.9%, respectively. 
This study also considered a group of allograft failures 
in patients who were retransplanted. A total of 119 
failures were classified into three diagnostic categories 
based on clinical and pathologic assessment as previously 
described.'! These were rejection (n - 53), primary 
non function (n - 31), and other causes of failure includ-
ing vascular thrombosis, infections. and "technical" com-
plications (n - 33). The frequency of rejection as the 
cause of transplant failure was the lowest in liver allo-
grafts with zero mismatches. especially for HLA-DR, but 
also for HLA-A and HLA-B. Increased HLA incompati-
bility was associated with higher incidence of rejection. 
On the other hand, primary non function occurred rela-
tively more often with HLA-DR compatible liver trans-
plants, whereas the incidence of other causes of liver 
allograft failure was associated with HLA-A- or -8-
compatible liver transplants. 
DISCUSSION 
These data demonstrate that HLA compat-
ibility is associated with a decreased survival 
of liver transplants. The effect was noted for 
both class I antigens of HLA-A and class II 
antigens of the HLA-DR locus. The present 
findings are in contrast to the widely reported 
beneficial effect of HLA compatibility on 
kidney transplant outcome. I•2 
Our inability to demonstrate a beneficial 
effect of matching for HLA on liver trans-
plant survival does not necessarily conflict 
with the concept that HLA influences trans-
plant rejection of liver allografts. This is 
apparent from our observations that the fre-
quency of liver transplant failures due to 
rejection correlated with the degree of HLA 
mismatching, especially for HLA-DR. Be-
sides transplant rejection induced by HLA 
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incompatibility, other immunologic mecha-
nisms may be responsible for liver transplant 
failure. These mechanisms could be specific 
for a variety of antigens, including viral anti-
gens, autoantigens, and tissue-specific compo-
nents. 
Particular consideration must be given to 
the influence of HLA, especially in view of its 
role in cellular interactions during the 
immune response. This phenomenon is 
referred to as major histocompatibility com-
plex (MHC) restriction and has been widely 
observed in human and animal models of 
immune responsiveness. Many cellular inter-
actions during the immune response are HLA 
restricted, that is, they are efficient only if the 
cells involved express shared HLA antigens. 
This MHC restriction (or self-recognition) 
has been demonstrated in interactions 
between antigen-presenting cells and T lym-
phocytes and in cytotoxic T cell-induced lysis 
of virus-infected and other antigen-expressing 
target cells. HLA restriction has been demon-
strated for cellular immunity to clinically 
MARKUS ET AL 
relevant viral antigens such as hepatitis B 
virus, cytomegalovirus, and Epstein-Barr 
viruS. I4-16 During infection, cytotoxic lympho-
cyte-mediated damage would probably be 
more efficient if infected target cells in the 
allograft express compatible HLA antigens. 
The phenomenon of HLA restriction has 
not been extensively studied in autoimmune 
liver diseases because the antigens involved 
are largely undefined. However, HLA has 
been indirectly implemented through its asso-
ciation with several liver diseases including 
chronic active hepatitis and sclerosing cholan-
gitis. 17 These processes would not only affect 
the original liver, but also may contribute to 
recurrent disease of the transplanted liver, 
especially from an HLA-compatible donor. 
Thus, the concept should be raised that 
HLA compatibility may have a dualistic 
effect on liver transplant outcome: On one 
hand it reduces the rejection process, whereas 
on the other hand, it may enhance other 
immunologic mechanisms leading to allograft 
dysfunction. 
REFERENCES 
I. Cecka JM: In Terasaki PI (ed) Clinical Kidney 
Transplants 1986. Los Angeles, UCLA Tissue Typing 
Laboratory, 1986, p 141 
2. OpelzG: Transplant Proc 19:641, 1987 
3. Yacoub M, Festenstein p, Doyle p, et al: Transplant 
Proc 19:2487, 1987 
3. Starzl TE, Iwatsuki S, Van Thiel DH, et al: Hepa· 
tology 2:614, 1982 
5. Malatack 11, Zitelli BJ, Gartner JC Jr, et al: 
Transplant Proc IS: 1292. 1983 
6. Markus BH. Fung JJ, Gordon RD, et al: Transplant 
Proc 19:63, 1987 (suppI3) 
7. Starzl TE, Ishikawa M, Putnam CW, et al: Trans-
plant Proc 6: 129, 1974 (suppl) 
8. Iwatsuki S, Rabin BS, Shaw BW Jr, et al: Trans-
plant Proc 16:1427, 1984 
9. Gordon RD. Fung 11, Markus BM, et al: Surgery 
100:705, 1986 
10. Fung 11, Zeevi A, Starzl TE, et al: Hum Immunol 
16:182, 1986 
II. Markus BH, Fung 11, Zeevi A, et al: Transplant 
Proc 19:2470, 1987 
12. Markus BH, Duquesnoy RJ, Gordon RD, et al: 
submitted for publication 
13. Shaw BW Jr, Gordon RG, Iwatsuki S, et al: Semin 
Liver Dis 5:394, 1985 
14. Quinnan GV Jr, Kirmani N, Esber E, et al: J 
ImmunoI126:2036,1981 
15. Lindsley MD, Torpey DJ III, Rinaldo CR Jr: J 
Immunol136: 3045, 1986 
16. Misko IS, Moss DJ, Pope JH: Proc Nat! Acad Sci 
USA 77:4247,1980 
17. Tiwari JL, Terasaki PI: HLA and disease associa-
tions. New York, Springer, 1985 
lJ 
1 
or. 
enf 
In 
idi, 
stu 
as 
me 
tio 
lyr 
ity 
SUI 
no; 
do 
an 
we 
Wt 
at' 
stl 
Ig 
se: 
sp 
xe 
na 
in 
fa 
af 
E 
Se 
Tr 
